Foguth Wealth Management LLC. Buys New Stake in Amgen Inc. $AMGN

Foguth Wealth Management LLC. purchased a new stake in Amgen Inc. (NASDAQ:AMGN) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,448 shares of the medical research company’s stock, valued at approximately $488,000.

A number of other institutional investors have also modified their holdings of AMGN. Anfield Capital Management LLC lifted its holdings in shares of Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares during the period. Dogwood Wealth Management LLC grew its holdings in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the period. Tower View Wealth Management LLC raised its position in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares in the last quarter. Manning & Napier Advisors LLC raised its position in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new position in Amgen in the fourth quarter valued at approximately $34,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on AMGN shares. Guggenheim upped their price objective on Amgen from $340.00 to $343.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $350.00 target price on shares of Amgen in a report on Monday, July 6th. Argus decreased their target price on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, May 20th. Morgan Stanley lowered their price target on shares of Amgen from $340.00 to $333.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 8th. Finally, Weiss Ratings lowered shares of Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $357.00.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: The European Medicines Agency’s CHMP issued a positive opinion recommending broader use of Repatha to reduce cardiovascular risk in high-risk adults without a prior heart attack or stroke. The recommendation, based on Phase 3 data showing fewer major cardiovascular events, could expand Repatha’s addressable market in Europe. Amgen Wins Backing in Europe for Broader Repatha Use
• Positive Sentiment: Amgen declared a quarterly dividend of $2.52 per share, payable September 11 to shareholders of record on August 21. The ongoing payout, equivalent to $10.08 annually and an indicated yield of about 2.6%, supports the stock’s income appeal and signals continued confidence in cash generation. Amgen Announces 2026 Third Quarter Dividend
• Positive Sentiment: Amgen launched its first Amgen Scholars Program in India at IIIT Hyderabad. Although not a near-term financial driver, the initiative may strengthen the company’s research talent pipeline and scientific relationships. First Amgen Scholars Program in India Launches
• Neutral Sentiment: Wall Street’s attention is centered on second-quarter results. Amgen has a history of earnings beats, but investors will scrutinize product-sales trends, guidance and progress on MariTide, making the report a significant near-term catalyst. Amgen Q2 Earnings Preview
• Negative Sentiment: Barclays raised its price target to $360 but retained a Hold rating. With the target below the recent trading level, the update reinforces concerns that much of Amgen’s positive outlook may already be reflected in the shares. Barclays Boosts Amgen Price Target

Amgen Stock Down 0.6%

Amgen stock opened at $385.16 on Friday. The stock has a market capitalization of $207.87 billion, a PE ratio of 26.80, a price-to-earnings-growth ratio of 3.90 and a beta of 0.41. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $398.00. The business has a 50 day simple moving average of $356.60 and a 200-day simple moving average of $353.77. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the prior year, the company posted $4.90 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. On average, analysts anticipate that Amgen Inc. will post 22.31 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s payout ratio is presently 70.15%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.